Why was IGF-1R an oncology target?

Its signalling promotes proliferation and opposes apoptosis, and Laron syndrome supplied a human genetic argument that the axis matters in cancer.

What happened to those programmes?

They largely failed. Chen's 2013 review is titled 'trials and tribulations', which conveys the outcome accurately.

Does the failure disprove the biology?

No. Lifelong congenital absence and late blockade in established disease are different interventions. Prevention and treatment are different problems.

IGF-1 LR3

A Strong Rationale That Did Not Translate

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

The IGF-1 receptor was an attractive oncology target because IGF-1 signalling promotes proliferation and opposes cell death. Chen reviewed the programmes in 2013 under the title trials and tribulations, and Yee reviewed anti-IGF therapy in breast cancer in 2018.

Key facts

Target: IGF-1 receptor (IGF-1R)
Rationale: Proliferative and anti-apoptotic signalling
Chen 2013: Chin J Cancer (PMID 23601239)
Yee 2018: J Mol Endocrinol (PMID 29378771)
Outcome: Programmes largely unsuccessful
Complication: Insulin receptor similarity

Why the target looked so promising

IGF-1 receptor signalling drives proliferation and suppresses apoptosis, and elevated signalling had been associated with several cancers. Laron syndrome supplied the human genetic argument. Blocking the receptor should therefore remove a growth signal tumours were using — about as clean a rationale as oncology target selection produces.

What happened instead

Chen titled the 2013 review trials and tribulations, which conveys the outcome. Multiple agents entered clinical development and the programmes largely did not deliver the benefit the biology predicted. Yee's 2018 review of anti-IGF therapy in breast cancer covers the same territory in one disease.

Research material referenced

IGF-1 LR3 1mg — third-party HPLC tested

View — £37.99

The insulin receptor problem

The IGF-1 receptor and the insulin receptor are structurally close and can form hybrid receptors containing subunits of both. That creates two difficulties: achieving selectivity is hard, and blocking IGF-1R can disturb glucose handling. A target that cannot be engaged without touching insulin signalling has a narrow therapeutic window before anything else is considered.

Redundancy as the deeper problem

Tumours generally depend on more than one growth pathway. Removing one signal frequently produces compensation through another, which is why single-pathway inhibition so often disappoints in oncology. IGF-1R blockade appears to be a clear instance of that pattern rather than an exception to it.

Why the failure does not refute the biology

Laron syndrome concerns lifelong congenital absence of a signal. An antibody given to an adult with established disease is a different intervention entirely — different timing, different completeness, different starting point. A pathway can genuinely matter for whether cancer arises over decades while blocking it late changes little. Prevention and treatment are different problems.

What this contributes to reading any mechanism claim

That a strong biological rationale, supported by human genetics, is not sufficient. The distance between a mechanism being real and an intervention working is where most drug development fails, and this is one of the better-documented examples of that distance.

Extended research context

The IGF-1 LR3 deep dive

Deep dive: the design that runs backwards from everything else here

Almost every engineered compound in this catalogue solves the same problem in the same direction. Semaglutide attaches a C18 diacid, retatrutide and tirzepatide a C20, all to bind serum albumin and extend duration. CJC-1295's DAC goes further and binds albumin covalently at Cys34. The strategy throughout is to add binding, so the molecule survives longer in circulation. IGF-1 LR3 does the reverse. Its two modifications - arginine replacing glutamate at position 3, and a thirteen-residue N-terminal extension - exist to REMOVE binding, specifically to the IGF binding proteins that sequester the overwhelming majority of circulating IGF-1 in a ternary complex with IGFBP-3 and the acid-labile subunit. Same bound-free equilibrium, engineered in the opposite direction. The reason is that the two families face opposite constraints: an incretin peptide is cleared too fast to be useful, while IGF-1 is held too tightly to be available. Baxter's 1994 review in Hormone Research is the standard account of just how tightly.

Deep dive: a certificate written for the wrong failure mode

This is a recombinant protein, and it fails differently from everything else on this site. A synthetic peptide accumulates deletion sequences, because each coupling is slightly less than complete - at 99% efficiency a 39-mer finishes around 68% full-length, and those impurities differ by one residue's mass and show up in a mass spectrum. Ribosomal synthesis does not fail that way at all; a host cell builds the protein correctly or not at all. What contaminates the product instead is everything else the cell contained: host cell proteins, host DNA, and in bacterial systems endotoxin, which is not a protein, does not appear in a protein purity figure, and needs its own assay entirely. Layered on top is a failure mode with no peptide equivalent. This protein has three disulfide bonds, meaning six cysteines that can pair fifteen ways of which one is correct - and Milner and colleagues showed in the Biochemical Journal in 1995 that B-domain mutations influence oxidative folding, which is directly relevant since position 3 sits in the B-domain. A misfolded isomer has identical mass, identical composition, and is invisible to mass spectrometry. A certificate reading exactly like a synthetic peptide's is testing for problems this production route does not have while missing the ones it does.

Deep dive: an approved relative, and why that raises the risk rather than lowering it

Unusually for this catalogue, a licensed IGF-1 medicine exists. Mecasermin, marketed as Increlex, is recombinant human IGF-1 with an FDA label and a subcutaneous route, used in severe primary IGF-1 deficiency - Petriczko and colleagues reported on it in 2019 and Denaite and colleagues in Frontiers in Pediatrics in 2024. That is a real approval with real clinical evidence. It covers the native seventy-residue hormone. LR3 is an eighty-three-residue engineered analogue whose defining feature is deliberately altered binding behaviour, holds no marketing authorisation anywhere, and has essentially no primary literature under its own name - searches for IGF-1 LR3 and Long R3 IGF-1 return nothing. A nearby approval invites the inference that the analogue is somehow covered by it, and that inference is the most consequential error available in this category. Separately and unconditionally: IGF-1 and its analogues sit in WADA class S2, prohibited at all times, with the list extending to related substances and mimetics precisely so that structural modification creates no exemption.

Research applications

▸Cell culture supplementation where secreted IGFBPs confound dosing
▸IGF binding protein interaction and affinity studies
▸Recombinant protein expression and purification methodology
▸Disulfide folding and oxidative refolding research
▸Comparative work on engineered versus native growth factors
▸Anti-doping analytical method development

Handling checklist

✓Expect no PubChem record - proteins are indexed in UniProt (native IGF-1 is P05019)
✓Read the certificate for host cell protein, host DNA and endotoxin, not deletion sequences
✓Understand that mass spectrometry cannot detect a misfolded disulfide isomer
✓Treat loss of fold as the principal failure mode - it leaves mass unchanged
✓Avoid shaking and foaming; interfaces unfold proteins and aggregation is irreversible
✓Use low-binding consumables; adsorption is significant at microgram quantities
✓Aliquot before freezing - freeze-thaw is worse for a folded protein than a short peptide

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Reading mecasermin's approval as covering IGF-1 LR3

Fix: Increlex is native 70-residue rhIGF-1. LR3 is an 83-residue engineered analogue with altered binding, unlicensed everywhere. The approval does not transfer.

✗ Expecting a synthetic-peptide certificate for a recombinant protein

Fix: There are no deletion sequences here. The relevant tests are host cell protein, host DNA, endotoxin and something addressing conformation.

✗ Treating a clean mass spectrum as proof the protein is intact

Fix: A misfolded disulfide isomer has identical mass and composition. Only an activity or conformational assay addresses folding.

✗ Assuming absence from PubChem is a red flag

Fix: It is expected for a protein of this size - PubChem indexes small molecules, UniProt indexes proteins. This is unlike retatrutide, where absence is genuinely odd.

✗ Reading the cell-culture rationale as transferable

Fix: Bypassing IGFBP regulation is useful in a dish, where it is an experimental nuisance. In an organism the same system regulates a growth factor acting on nearly every tissue.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Why was IGF-1R an oncology target?: Its signalling promotes proliferation and opposes apoptosis, and Laron syndrome supplied a human genetic argument that the axis matters in cancer.
What happened to those programmes?: They largely failed. Chen's 2013 review is titled 'trials and tribulations', which conveys the outcome accurately.
Does the failure disprove the biology?: No. Lifelong congenital absence and late blockade in established disease are different interventions. Prevention and treatment are different problems.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum